These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23008280)

  • 41. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT; Wilson EM; Shapiro DJ
    J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor.
    Tachachartvanich P; Singam ERA; Durkin KA; Furlow JD; Smith MT; La Merrill MA
    J Hazard Mater; 2022 May; 429():128243. PubMed ID: 35093747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-androgenic activities of environmental pesticides in the MDA-kb2 reporter cell line.
    Aït-Aïssa S; Laskowski S; Laville N; Porcher JM; Brion F
    Toxicol In Vitro; 2010 Oct; 24(7):1979-85. PubMed ID: 20736058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steroid receptor profiling of vinclozolin and its primary metabolites.
    Molina-Molina JM; Hillenweck A; Jouanin I; Zalko D; Cravedi JP; Fernández MF; Pillon A; Nicolas JC; Olea N; Balaguer P
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):44-54. PubMed ID: 16750840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A bufadienolide derived androgen receptor antagonist with inhibitory activities against prostate cancer cells.
    Tian HY; Yuan XF; Jin L; Li J; Luo C; Ye WC; Jiang RW
    Chem Biol Interact; 2014 Jan; 207():16-22. PubMed ID: 24211617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
    Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
    J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural basis for androgen receptor agonists and antagonists: interaction of SPEED 98-listed chemicals and related compounds with the androgen receptor based on an in vitro reporter gene assay and 3D-QSAR.
    Tamura H; Ishimoto Y; Fujikawa T; Aoyama H; Yoshikawa H; Akamatsu M
    Bioorg Med Chem; 2006 Nov; 14(21):7160-74. PubMed ID: 16876421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and Validation of a Computational Model for Androgen Receptor Activity.
    Kleinstreuer NC; Ceger P; Watt ED; Martin M; Houck K; Browne P; Thomas RS; Casey WM; Dix DJ; Allen D; Sakamuru S; Xia M; Huang R; Judson R
    Chem Res Toxicol; 2017 Apr; 30(4):946-964. PubMed ID: 27933809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo and in vitro anti-androgenic effects of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture.
    Stoker TE; Cooper RL; Lambright CS; Wilson VS; Furr J; Gray LE
    Toxicol Appl Pharmacol; 2005 Aug; 207(1):78-88. PubMed ID: 16005038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cumulative effects of in utero administration of mixtures of reproductive toxicants that disrupt common target tissues via diverse mechanisms of toxicity.
    Rider CV; Furr JR; Wilson VS; Gray LE
    Int J Androl; 2010 Apr; 33(2):443-62. PubMed ID: 20487044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a group of brominated flame retardants as novel androgen receptor antagonists and potential neuronal and endocrine disrupters.
    Kharlyngdoh JB; Pradhan A; Asnake S; Walstad A; Ivarsson P; Olsson PE
    Environ Int; 2015 Jan; 74():60-70. PubMed ID: 25454221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.
    Yang SH; Song CH; Van HT; Park E; Khadka DB; Gong EY; Lee K; Cho WJ
    J Med Chem; 2013 Apr; 56(8):3414-8. PubMed ID: 23527816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR; Mishra SK; Karnes RJ; Saleem M
    Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen receptor-mediated non-genomic effects of vinclozolin on porcine ovarian follicles and isolated granulosa cells: Vinclozolin and non-genomic effects in porcine ovarian follicles.
    Wartalski K; Knet-Seweryn M; Hoja-Lukowicz D; Tabarowski Z; Duda M
    Acta Histochem; 2016 May; 118(4):377-86. PubMed ID: 27094116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.